|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 285.50 TWD | -2.39% |
|
+1.24% | +0.88% |
| 01-06 | Alvotech CEO Robert Wessman to Step Down in Early 2026, Lisa Graver Named Successor | MT |
| 01-06 | Lisa Graver to Step Down from the Board of Alvotech | CI |
Company Valuation: Lotus Pharmaceutical Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 19,628 | 25,569 | 64,462 | 71,935 | 71,524 | 75,081 | 75,081 | - |
| Change | - | 30.27% | 152.11% | 11.59% | -0.57% | 4.97% | 0% | - |
| Enterprise Value (EV) 1 | 23,614 | 29,450 | 71,231 | 80,194 | 78,882 | 77,603 | 83,941 | 83,051 |
| Change | - | 24.72% | 141.87% | 12.58% | -1.64% | -1.62% | 8.17% | -1.06% |
| P/E ratio | 19x | 17.8x | 21.2x | 17.3x | 13.9x | 16x | 10.4x | 8.5x |
| PBR | 2.24x | 2.31x | 4.62x | 4.1x | 3.33x | 3.34x | 2.49x | 2.18x |
| PEG | - | 0.6x | 0x | 0.5x | 0.6x | -2.07x | 0.2x | 0.4x |
| Capitalization / Revenue | 1.83x | 2.02x | 4.41x | 4.24x | 3.85x | 3.82x | 2.36x | 1.99x |
| EV / Revenue | 2.2x | 2.33x | 4.87x | 4.73x | 4.24x | 3.94x | 2.64x | 2.2x |
| EV / EBITDA | 10.2x | 9.64x | 14.1x | 13.1x | 10.8x | 10.6x | 6.83x | 5.98x |
| EV / EBIT | 14.6x | 12.8x | 17.3x | 16.4x | 13.1x | 13.1x | 8.45x | 6.72x |
| EV / FCF | 15.4x | -65x | 22.7x | 66.6x | 13.6x | 13.3x | 30x | 11x |
| FCF Yield | 6.5% | -1.54% | 4.41% | 1.5% | 7.35% | 7.51% | 3.33% | 9.06% |
| Dividend per Share 2 | - | 1.93 | 3.46 | 4.66 | 5.73 | 5.4 | 7.57 | 8.78 |
| Rate of return | - | 1.98% | 1.41% | 1.71% | 2.13% | 1.89% | 2.65% | 3.08% |
| EPS 2 | 4.22 | 5.47 | 11.59 | 15.72 | 19.35 | 17.86 | 27.34 | 33.57 |
| Distribution rate | - | 35.3% | 29.9% | 29.6% | 29.6% | 30.2% | 27.7% | 26.2% |
| Net sales 1 | 10,729 | 12,649 | 14,633 | 16,958 | 18,584 | 19,680 | 31,842 | 37,716 |
| EBITDA 1 | 2,322 | 3,054 | 5,048 | 6,114 | 7,303 | 7,324 | 12,290 | 13,878 |
| EBIT 1 | 1,613 | 2,295 | 4,111 | 4,903 | 6,020 | 5,908 | 9,936 | 12,361 |
| Net income 1 | 1,030 | 1,403 | 3,021 | 4,106 | 5,066 | 4,697 | 7,221 | 8,850 |
| Net Debt 1 | 3,986 | 3,881 | 6,769 | 8,259 | 7,358 | 2,522 | 8,860 | 7,970 |
| Reference price 2 | 80.00 | 97.50 | 246.00 | 272.00 | 269.50 | 285.50 | 285.50 | 285.50 |
| Nbr of stocks (in thousands) | 245,354 | 262,246 | 262,041 | 264,468 | 265,394 | 262,980 | 262,980 | - |
| Announcement Date | 3/26/21 | 3/16/22 | 3/14/23 | 3/15/24 | 3/7/25 | - | - | - |
1TWD in Million2TWD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 16.38x | 4.04x | 10.85x | 1.85% | 2.43B | |
| 46.47x | 15.39x | 34.15x | 0.55% | 952B | |
| 19.66x | 5.52x | 15.38x | 2.53% | 492B | |
| 74.58x | 7.29x | 17.31x | 2.97% | 389B | |
| 19.48x | 4.96x | 12.35x | 2.9% | 363B | |
| 28.79x | 5.41x | 16.04x | 1.69% | 296B | |
| 14.2x | 4.62x | 9.95x | 2.93% | 274B | |
| 19.94x | 5.27x | 12.38x | 2.87% | 273B | |
| 16.55x | 5.85x | 12.09x | 3.05% | 264B | |
| 25.78x | 6.06x | 10.38x | 2.93% | 176B | |
| Average | 28.18x | 6.44x | 15.09x | 2.43% | 348.15B | |
| Weighted average by Cap. | 33.55x | 8.31x | 19.30x | 2.12% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- 1795 Stock
- Valuation Lotus Pharmaceutical Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition